Abstract P4-22-21: NCI9782: A phase 1 study of talazoparib in combination with carboplatin and paclitaxel in patients with advanced solid tumors

Conclusion: PARP inhibition with talazoparib days 1-7 in combination with carboplatin and paclitaxel leads to DLT of myelosuppression. However, clinical responses are seen even with lower dose combinations.Citation Format: Turk A, Chan N, Leal T, O'Regan R, Tevaarwerk A, Rice L, Campbell T, Barroilhet L, Mehnert J, Eickhoff J, Kolesar J, Liu G, Wisinski K. NCI9782: A phase 1 study of talazoparib in combination with carboplatin and paclitaxel in patients with advanced solid tumors [abstract]. In: Proceedings of the Thirty-Ninth Annual CTRC-AACR San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P4-22-21.
Source: Cancer Research - Category: Cancer & Oncology Authors: Tags: Poster Session Abstracts Source Type: research

Related Links:

SMAD4 is the only common SMAD in TGF-β signaling that usually impedes immune cell activation in the tumor microenvironment. However, we demonstrated here that selective deletion of Smad4 in NK cells actually led to dramatically reduced tumor cell rejection and augmented tumor cell metastases, reduced murine CMV clearance, as well as impeded NK cell homeostasis and maturation. This was associated with a downregulation of granzyme B (Gzmb), Kit, and Prdm1 in Smad4-deficient NK cells. We further unveiled the mechanism by which SMAD4 promotes Gzmb expression. Gzmb was identified as a direct target of a transcriptional com...
Source: Journal of Clinical Investigation - Category: Biomedical Science Authors: Source Type: research
The stroma of solid tumors can exclude or limit immune infiltration, or lead to the recruitment of tumor-promoting rather than tumor-attacking immune cells. This finding was reported by Jayaprakash et al. in this issue of the JCI, and it was particularly prominent in the hypoxic zones of tumors in the transgenic adenocarcinoma of the mouse prostate (TRAMP) cancer models. A current clinical goal of immune checkpoint blockade (ICB) is to extend its utility to more patients by converting immunologically “cold” tumors that do not provoke a strong immunological response to “hot” tumors that are invaded b...
Source: Journal of Clinical Investigation - Category: Biomedical Science Authors: Source Type: research
Despite the success of immune checkpoint blockade against melanoma, many “cold” tumors like prostate cancer remain unresponsive. We found that hypoxic zones were prevalent across preclinical prostate cancer and resisted T cell infiltration even in the context of CTLA-4 and PD-1 blockade. We demonstrated that the hypoxia-activated prodrug TH-302 reduces or eliminates hypoxia in these tumors. Combination therapy with this hypoxia-prodrug and checkpoint blockade cooperated to cure more than 80% of tumors in the transgenic adenocarcinoma of the mouse prostate–derived (TRAMP-derived) TRAMP-C2 model. Immunofluo...
Source: Journal of Clinical Investigation - Category: Biomedical Science Authors: Source Type: research
The paper, titled 'Debt or Death?', used data on 9.5 million nationally-representative patients between 1998 and 2014, who spend an average of $92,098 a year trying to stay alive.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news
Source: Peerview CME/CE Video Podcast - Internal Medicine International - Category: Internal Medicine Authors: Tags: Science, Medicine Source Type: video
Conclusion: GSTP1 and CYPs expressions are increased in intracranial tumors. These results should be confirmed with larger series and different enzyme subtypes.
Source: Medical Principles and Practice - Category: Internal Medicine Source Type: research
The start-up ’s optofluidic system could help get personalized cancer cell therapies to more people
Source: Chemical and Engineering News - Category: Chemistry Authors: Source Type: research
Publication date: Available online 15 October 2018Source: European Journal of Surgical OncologyAuthor(s): Han-Yu Deng, Liang Hou, Panpan Zha, Kai-Li Huang, Lei PengAbstractBackgroundWhether sarcopenia has any impact on long-term survival of patients with surgically treated non-small cell lung cancer (NSCLC) remains unclear. We conducted a meta-analysis focusing on current topic comprehensively for the first time.MethodsWe systematically searched relevant studies in PubMed, Embase, and Cochrane Library up to July 3, 2018. Data of 5-year overall survival (OS) and disease-free survival (DFS) rates as well as hazard ratio (HR)...
Source: European Journal of Surgical Oncology (EJSO) - Category: Surgery Source Type: research
Three-dimensional mammography screening detected 34 percent more breast cancer tumors than the traditional process of a single image, according to a study.
Source: Health News - UPI.com - Category: Consumer Health News Source Type: news
Conclusion: The presented score is a simple and early predictor of both short- and long-term outcomes and identifies patients who should undergo rapid volume expansion to counteract hemoconcentration, the spreading of microvascular thrombosis, and the consequent increased organ damage.What is Known:• In eHUS, hemoconcentration is associated with worse short- and long-term outcome.• A prognostic index to identify patients at higher risk for complications at presentation is not available.What is New:• We developed a simple and early prognostic index for eHUS outcome with the combination of Hb and sCr at onset,...
Source: European Journal of Pediatrics - Category: Pediatrics Source Type: research
More News: Anemia | Brain | Brain Cancers | Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Gastroschisis Repair | Hematology | Neurology | Oral Cancer | Oropharyngeal Cancer | Ovarian Cancer | Ovaries | Pancreas | Pancreatic Cancer | Radiography | Study | Thrombocytopenia | Toxicology